Epizyme Inc. (NASDAQ:EPZM), whose market capitalization now stands at $886.82M, reported EPS of $-2.07 in the last financial year. That indicates the stock has price-to-earnings ratio of – at the prevailing stock price. This fiscal year’s EPS is projected to grow 41.90% over the preceding year.
For the forward P/E metric, market analysts have a 12-month target price of $24.38 on the stock of Epizyme, Inc..
Over the preceding five years, Epizyme, Inc. has recorded EPS improvement of 33.30%. That against sales growth of 2.90% over the same 5-year period.
Let’s look into the charts of the stock
The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.
Epizyme, Inc. also recorded return assets of -45.40%, return on of -55.40% and return on investments of -55.30%.
Analysts are projecting the stock of Epizyme, Inc. to be trading at $24.38 in the next 12-months, but what been its performance quality until now?
The stock jumped/declined 26.64% in the previous week, and for the preceding month it is up/down -10.22%. For the quarter and for the fiscal year so far, the shares have risen/decline -14.45% and 19.83%, respectively. From a year earlier, the stock has moved 22.36%.
What about the volatility of the equity? First, the stock?s beta is 2.38. Investors would do well to note that beta of less than 1 indicates that the underlying security is less volatile as against the market, but beta over one implies that a security is extremely volatile compared to market.
In terms of monthly or weekly volatility, Epizyme, Inc. has a weekly volatility of 18.80% and monthly volatility of 10.72%.
Epizyme, Inc. EPZM announced positive interim data from an ongoing phase II study evaluating pipeline candidate tazemetostat, an oral EZH2 inhibitor, as a monotherapy in patients with relapsed or refractory follicular lymphoma (r/rFL) or diffuse large B-cell lymphoma (DLBCL) based on their EZH2 mutational status. The data were presented at the International Conference on Malignant Lymphoma (ICML).